Litcius/Paper detail

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial (AIO KRK 0314)

Dominik Paul Modest, Meinolf Karthaus, Stefan Kasper, Nicolas Moosmann, Verena Keitel, Alexander Kiani, Jens Uhlig, Lutz Jacobasch, Ludwig Fischer von Weikersthal, Martin Fuchs, Florian Kaiser, Christian Lerchenmüller, Dagmar Sent, Christian Junghanß, Swantje Held, Sylvie Lorenzen, Klaus Kaczirek, Andreas Jung, Sebastian Stintzing, Volker Heinemann

2022European Journal of Cancer11 citationsDOI

Topics & Concepts

FOLFOXPanitumumabMedicineColorectal cancerInternal medicineOncologyKRASOxaliplatinCancerHepatocellular Carcinoma Treatment and PrognosisColorectal Cancer Treatments and StudiesCancer Immunotherapy and Biomarkers
FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases – The PARLIM trial (AIO KRK 0314) | Litcius